InnoPath Therapeutics Welcomes Industry Veteran Dr. Vijendra Nalamothu as Chief Development Officer and Co-Founder
August 12, 2025 – Boston, MA – InnoPath Therapeutics, a preclinical-stage biopharmaceutical company specializing in innovative dermatology and oncology treatments, is proud to announce the appointment of Dr. Vijendra Nalamothu as Chief Development Officer and Co-Founder.
Dr. Vijendra Nalamothu, Chief Development Officer and Co-Founder, Innopath Therapeutics.
Dr. Nalamothu brings a remarkable track record in dermatological drug development and commercialization. As the Founder, CEO, and CSO of Tergus Pharma—now merged with MedPharm, Ltd. in July 2024—he played a pivotal role in advancing topical therapeutics and scaling CDMO operations.
His leadership trajectory includes steering global dermatology R&D at Promius Pharma and holding senior roles at Sanofi-Aventis’s Worldwide Dermatology division. Beyond his recent appointment by the Governor of North Carolina to the state’s Board of Science, Technology, and Innovation, he was honored in May 2025 with an honorary doctorate from the Philadelphia College of Pharmacy at Saint Joseph’s University, celebrating his remarkable contributions to pharmaceutical sciences.
“InnoPath is honored to have Dr. Nalamothu join our team,” said Peter Trepp, Chairman and CEO. “His deep expertise in life sciences strategy, dermatology R&D, and company-building will be instrumental as we move our pipeline toward clinical trials early next year.”
“I am truly energized to join InnoPath at this transformative moment,” said Dr. Vijendra Nalamothu. “The company’s commitment to precision science and bold, patient-focused innovation perfectly matches my own dedication to advancing dermatological therapeutics. Together, we’re poised to deliver pioneering treatments that will change lives and set new standards of care worldwide.”
About InnoPath Therapeutics
InnoPath Therapeutics is a preclinical-stage biotech innovator focused on targeted treatments for dermatological cancers and serious skin diseases. Leveraging advanced drug delivery platforms and regulatory know-how, InnoPath is driven by precision science to bring improved solutions to patients.
Media Contact
Andrea Miller
Senior Director, Product Development / Co-Founder
InnoPath Therapeutics
andrea@innopathtx.com
859-653-3215